BridgeBio Oncology Therapeutics, Inc.
BBOT
$11.07
-$0.28-2.47%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
12/3/2025
-
Market News Video
11/19/2025
-
TipRanks Financial Blog
11/18/2025
-
Globe Newswire
11/15/2025
-
24/7 Wall St.
11/15/2025
-
GuruFocus
11/13/2025
-
SeekingAlpha.com: All News
11/13/2025
-
TipRanks Financial Blog
11/12/2025
-
Globe Newswire
11/6/2025
-
ETF Channel
11/3/2025
-
Globe Newswire
10/30/2025
-
Globe Newswire
10/23/2025
-
Globe Newswire
10/13/2025
-
Globe Newswire
9/30/2025
-
ETF Channel
8/20/2025
-
Globe Newswire
8/17/2025
-
Simply Wall St
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of May 25 and 29 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 405 4770
Address
256 E. Grand Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide...
more